Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts.
Marinac CR et al. Br J Cancer. 2018 Mar 12. doi: 10.1038/s41416-018-0010-4. [Epub ahead of print].
Multidrug resistance 1 (MDR1/ABCB1) gene polymorphism (rs1045642 C > T) and susceptibility to multiple myeloma: a systematic review and meta-analysis.
Razi B et al. Hematology. 2018 Mar 1:1-7. doi: 10.1080/10245332.2018.1443897. [Epub ahead of print].
Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ et al. Biol Blood Marrow Transplant. 2018 Mar 1. pii: S1083-8791(18)30103-4. doi: 10.1016/j.bbmt.2018.02.017. [Epub ahead of print].
Development of an unbiased, semi-automated approach for classifying plasma cell immunophenotype following multicolor flow cytometry of bone marrow aspirates.
Post SR et al. Cytometry B Clin Cytom. 2018 Mar 24. doi: 10.1002/cyto.b.21635. [Epub ahead of print].
Risk factors for blood stream infections in Multiple Myeloma: A population-based study of 1154 patients in Denmark.
Sørrig R et al. Eur J Haematol. 2018 Mar 22. doi: 10.1111/ejh.13066. [Epub ahead of print].
Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.
Davies FE et al. Haematologica. 2018 Mar 22. pii: haematol.2017.177139. doi: 10.3324/haematol.2017.177139. [Epub ahead of print].
The pattern of Mesenchymal stem cell expression is an independent marker of outcome in multiple myeloma.
Schinke C et al. Clin Cancer Res. 2018 Mar 21. pii: clincanres.2627.2017. doi: 10.1158/1078-0432.CCR-17-2627. [Epub ahead of print].
Evaluation of neutrophil-to-lymphocyte ratio in newly diagnosed patients receiving borte- zomib-based therapy for multiple myeloma.
Zhou X et al. Cancer Biomark. 2018 Mar 2. doi: 10.3233/CBM-170795. [Epub ahead of print].
Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.
Wei X et al. Cancer Res. 2018 Mar 20. pii: canres.1900.2017. doi: 10.1158/0008-5472.CAN-17-1900. [Epub ahead of print].
Comparison of whole body magnetic resonance imaging (WBMRI) to whole body computed tomography (WBCT) or 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) in patients with myeloma: Systematic review of diagnostic performance.
Gariani J et al. Crit Rev Oncol Hematol. 2018 Apr;124:66-72. doi: 10.1016/j.critrevonc.2018.02.012. Epub 2018 Mar 2.